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DnaK is a molecular chaperone responsible for
multiple aspects of bacterial proteostasis. The intrin-
sically slow ATPase activity of DnaK is stimulated by
its co-chaperone, DnaJ, and these proteins often
work in concert. To identify inhibitors we screened
plant-derived extracts against a reconstituted
mixture of DnaK and DnaJ. This approach resulted
in the identification of flavonoids, includingmyricetin,
which inhibited activity by up to 75%. Interestingly,
myricetin prevented DnaJ-mediated stimulation of
ATPaseactivity,withminimal impact oneitherDnaK’s
intrinsic turnover rate or its stimulation by another co-
chaperone, GrpE. Using NMR, we found that myrice-
tin bindsDnaKatanunanticipated sitebetween the IB
and IIB subdomains and that it allosterically blocked
binding of DnaK to DnaJ. Together, these results
highlight a ‘‘gray box’’ screening approach, which
might facilitate the identification of inhibitors of other
protein-protein interactions.
INTRODUCTION
Many emerging drug targets operate as part of multi-protein
complexes in vivo (Gavin et al., 2002). Often, these ensembles
have a single enzymatic output, such as ATP consumption, that
is catalyzed by one core component. The nonenzyme partners
typically regulated this activity, by impacting subcellular localiza-
tion, substrate selection, and/or turnover rates. Because the
protein partners are often important for tuning biological function
and integrating information from signaling pathways, there is
interest in identifying molecules that specifically target the
protein-protein interactions in complexes (Arkin and Wells,
2004; MacBeath and Schreiber, 2000). Such inhibitors are often
identified by either screening for inhibitors of protein-protein
contacts in purified systems or by structure-guided design210 Chemistry & Biology 18, 210–221, February 25, 2011 ª2011 Else(Horswill et al., 2004; Kortemme and Baker, 2002; Magliery
et al., 2005; Vassilev et al., 2004; Yin and Hamilton, 2005). These
strategies are increasingly useful, but all in vitro screensareprone
to attrition when the active compounds are taken into cell-based
or animal systems. An alternative approach is to use ‘‘black box’’
cell-based, phenotypic screens. Cell-based approaches are
powerful because they incorporate multiple parameters, such
as an intact plasma membrane, a full complement of regulatory
pathways, and native multi-protein complexes, which better
approximate physiological states. However, it can often be
challenging to identify the inhibitor’s target(s). We have been
pursuing an approach that might be considered a compromise
between these platforms. In this strategy, multiple components
of a known protein complex are purified and reconstituted
in vitro (Changet al., 2008a;Miyata et al., 2010). Only one compo-
nent typically has measurable activity, yet the other, ancillary
partners are likely to impact the turnover rate, approximating
a more physiological enzymatic output. In addition, protein-
protein interactions between the core enzyme and its partners
might mask some potential drug-binding sites, while inducing
conformers that might reveal other latent sites. We term this
approach ‘‘gray box’’ because it is expected to find the middle
ground between biochemical and cell-based assays, providing
some limited amount of physiological complexity while reducing
investment in downstream target identification.
As a model system, we have principally focused on the
Escherichia coli DnaK protein, which belongs to the highly
conserved heat shock protein 70 (Hsp70) family. These molec-
ular chaperones participate in many aspects of cellular proteo-
stasis (Genevaux et al., 2007; Powers et al., 2009) and are
emerging drug targets (Evans et al., 2010). Like all Hsp70 family
members, DnaK consists of two domains: a 41 kDa nucleotide-
binding domain (NBD), which provides energy for the chaperone
machine by hydrolyzing ATP; and a 26 kDa substrate-binding
domain (SBD), which binds to the exposed hydrophobic regions
of unfolded or partially folded proteins (Bertelsen et al., 2009;
Chang et al., 2008b; Genevaux et al., 2007; Harrison et al.,
1997; Zhu et al., 1996). The NBD is further divided into four
subdomains, IA, IIA, IB, and IIB, which constitute a deep,
ATP-binding cleft (Harrison et al., 1997) (Figure 1A). The NBD isvier Ltd All rights reserved
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Figure 1. Screening Plant Extracts against the DnaK-DnaJ System Reveals ECG as the Major Inhibitor in White Tea
(A) Schematic of the DnaK chaperone, with the NBD, SBD, and the NBD subdomains (IA, IIA, IB, IIB) highlighted. The co-chaperones DnaJ and GrpE are shown
near their approximate binding sites on DnaK’s NBD.
(B) Results of the screen of natural product extracts (40 mg/ml) against the ATPase activity of the DnaK (0.6 mM) and DnaJ (1 mM). Each extract was screened in
duplicate, and the range is shown relative to a solvent control. The active compounds (>25% inhibition) are shown in open symbols (Table S1).
(C) Chemical structure of ECG and its dose-dependent inhibition of DnaK-DnaJ. The active component of white tea was identified by bioassay-guided fraction-
ation and the structure confirmed by comparing the NMR spectra to an authentic sample (Figure S1). The dose-dependence experiment was performed against
DnaK-DnaJ in triplicate, and the error bars represent standard error of the mean.
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to regulate interdomain allosteric crosstalk (Han and Christen,
2001; Swain et al., 2007) and link nucleotide state to substrate-
binding affinity. Briefly, the ATP-bound form of DnaK has
relatively poor affinity for its protein substrates, whereas the
ADP-bound state binds tightly (Buchberger et al., 1995; Szabo
et al., 1994).
Nucleotide turnover by DnaK is tightly controlled by co-
chaperones, including DnaJ and GrpE (Liberek et al., 1991).
DnaJ belongs to the Hsp40 family of co-chaperones, and it is
thought to bind the IA and IIA subdomains of DnaK (Gassler
et al., 1998; Jiang et al., 2007; Suh et al., 1998) (Figure 1A).
This protein-protein interaction allosterically stimulates the
ATPase activity of DnaK. In the presence of DnaJ, ADP release
becomes rate limiting, and another co-chaperone, GrpE, assists
nucleotide exchange via protein-protein interactions with the IB
and IIB subdomains (Harrison et al., 1997; Liberek et al., 1991).
Thus, the combination of DnaK, DnaJ, and GrpE efficiently turns
over ATP and allows control over chaperone activity (Liberek
et al., 1991; Russell et al., 1998; Schroder et al., 1993). Although
only the core chaperone, DnaK, has any enzymatic activity,
knockouts of DnaJ or GrpE share some phenotypes, such as
temperature sensitivity, in common with DdnaK cells (Ang
et al., 1986; Sell et al., 1990). These results suggest that the entire
network is required for efficient chaperone activity. Furthermore,
mutants that specifically disrupt interactions between DnaK
and DnaJ give similar phenotypes (Gassler et al., 1998), further
suggesting that protein-protein contacts among the compo-
nents are required.
Using this well-characterized system, we sought to develop
screens to specifically target the emergent properties of the
Dnak-DnaJ system. Namely, because ATP turnover is greatlyChemistry & Biology 18, 210accelerated by the DnaJ co-chaperone, we developed an
ATPase assay that measures turnover by the DnaK-DnaJ combi-
nation (Changetal., 2008a;Miyataet al., 2010).Here,wescreened
a library of plant-derived, natural product extracts and identified
myricetin as an inhibitor. Consistent with the screening design,
this compound selectively inhibited the DnaK-DnaJ complex
and had little activity against either DnaK alone or the DnaK-
GrpE combination. Unexpectedly, we found that myricetin bound
to the IB and IIB subdomains, approximately 20–30 A˚ away from
the DnaJ-DnaK interacting site, yet it appeared to allosterically
influence the DnaK-DnaJ interaction. Finally, we discuss how
this approach might provide a template for ‘‘gray box’’ screening
against other reconstituted multi-protein complexes in vitro.
RESULTS
Screening for Natural Products that Inhibit
the DnaK-DnaJ Complex
To initiate a screen for potential inhibitors of the DnaK-DnaJ
combination, we assembled a collection of organic extracts
from 36 commercial spices and crude plant materials. For this
specific studywe chose to use commonplantmaterials, contain-
ing largely known compounds, to facilitate downstream identifi-
cation of active components. Also, because the Hsp70-Hsp40
family is highly conserved and expressed in many plant patho-
gens, we were interested in whether natural product extracts
might be particularly enriched for inhibitors of this system.
This collection was arrayed in 96-well plates and screened at
40 mg/ml using a previously established, high-throughput
ATPase assay (Chang et al., 2008a). The key design criteria
included the use of high ATP concentrations (1 mM, > > Km) to
minimize discovery of nucleotide-competitive inhibitors. Second,–221, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 211
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Figure 2. The SAR of Flavonoid-Based Inhibitors of DnaK-DnaJ
(A) Approximately 80 flavonoids were chosen based on their structural similarity to EGC (Figure S2) and screened against the DnaK-DnaJ ATPase activity. The
activities of select examples are shown in relation to a DMSO solvent control. The ATPase assays were performed in triplicate, and the error bars represent stan-
dard error of the mean (DnaK, 0.6 mM; DnaJ, 1 mM).
(B) A summary of the SARs, highlighting the key structural features of the flavonoid scaffold important for activity against DnaK-DnaJ.
(C) Summary of the functional group decoration and activity of select flavonoids. These examples were selected to highlight key SAR observations.
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Allosteric Inhibitor of a Protein Complexwe employed an optimized ratio of DnaK (0.6 mM) to DnaJ (1 mM)
that gives robust ATP turnover and good Z0 scores (0.6), to favor
identificationof inhibitors (Changet al., 2008a;Miyataet al., 2010).
Using this approach, we screened each crude extract in triplicate
and found that only six of 36 extracts (allspice, black tea, cocoa,
cinnamon, cloves, and white tea) inhibited ATPase activity by
more than 30% (Figure 1B; see Table S1 available online). Using
activity-guided fractionation on reverse-phase HPLC columns,
we identified the major active component from the white tea
extract as epicatechin-3-gallate (ECG) (Figure 1C; Figure S1).
ECG is known to be prevalent in this plant (Friedman, 2007).
In dose-dependence experiments the IC50 of authentic ECG
was 6.0 ± 0.9 mM against the DnaK-DnaJ system (Figure 1C).
Identification of the Structure-Activity Relationships
of Flavonoid-Based Inhibitors
ECG is a member of a large family of plant-derived flavonoids
that possess a variety of antioxidation and other activities212 Chemistry & Biology 18, 210–221, February 25, 2011 ª2011 Else(Friedman, 2007; Khan and Mukhtar, 2008). Although these
well-known scaffolds often have modest selectivity, they can
be powerful probes for identifying new drug-binding sites (Cuc-
cioloni et al., 2009; Shapiro, 2004). Therefore, we chose to further
explore the SARs of flavonoids in the specific context of the
DnaK-DnaJ system. Toward that goal, we collected 80 related
flavonoids (structures available in Figure S2) and determined
their activity against DnaK-DnaJ (Figure 2A). This approach
provided a number of key SAR observations, which are summa-
rized in Figure 2B. For example we found that the free phenolic
groups on ring A were required for activity; quercetin provided
up to 67% inhibition (IC50 = 27.6 mM), whereas its tetramethoxy
derivative, quercetin tetramethyl (5,7,30,40) ether (QTE), had no
significant activity (IC50 > 200 mM) (Figure 2C). Most strikingly,
rhamnetin, which differs from quercetin only by a 7-methoxy
substitution on ring A, was also inactive, suggesting a particularly
important role for the C7 phenolic group (Figure 2C). On ring B,
hydroxyl groups at the 30, 40, and 50 positions appeared tovier Ltd All rights reserved
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Allosteric Inhibitor of a Protein Compleximprove activity. For example, myricetin, with hydroxyls at all
three positions, provided the highest percent inhibition (75% at
200 mM; IC50 = 14.5 mM), whereas the 4
0 mono-hydroxylated
kaempferol lacked activity (IC50 > 200 mM) (Figure 2C). On ring
C we found that, although the alkene was clearly required, the
hydroxyl group on position 3 made only minor contributions to
activity, as revealed by comparing myricetin and quercetin to
their counterparts lacking this modification, hieracin (IC50 =
28.2 mM) and luteolin (IC50 = 9.4 mM) (Figure 2C). It is worth noting
that ECG and epigallocatechin 3-gallate (EGCG), which contain
an extra gallate group appended to ring C, did not fit the general
SAR patterns, which might suggest that they have a different
binding mode (Figure 2C). Because myricetin provided the
best overall inhibition, we chose to further characterize its
binding and mechanism.
Myricetin Binds to the IB and IIB Subdomains of DnaK
To gain insight into how flavonoids inhibit ATPase activity, we
first performed nuclear magnetic resonance (NMR) experiments
to examine whether the compound might bind DnaK. In these
studies, 1H-15N labeled DnaK NBD (250 mM, in the presence of
1 mM ADP) was titrated with myricetin, and a two-dimensional
1H-15N HSQC-TROSY experiment was performed. These exper-
iments revealed a set of chemical shift perturbations mainly in
the IB and IIB subdomains facing the nucleotide binding cleft,
along with scattered residues of the IA and IIA (Figure 3A;
Figure S3A). Interestingly, these results suggested that myricetin
did not bind to the same sites as ATP or DnaJ; instead, the
binding site appeared to be in a distinct location ‘‘above’’ the
nucleotide-binding cleft (Figure 3A).
To further explore thismodel,weused intrinsic tryptophan fluo-
rescence to study myricetin-induced, structural changes in
DnaK. This chaperone has a single tryptophan (Trp102), which
is present at the NBD-SBD interface, which has been extensively
used as a probe for nucleotide-induced structural transitions
(Buchberger et al., 1995). Briefly, ATP is known to induce a blue
shift (349–345 nm), with a corresponding 18% decrease in inten-
sity (Buchberger et al., 1995; Theyssen et al., 1996). When we
saturatedDnaKwithmyricetin (100mM), tryptophan fluorescence
responded normally to ATP binding, suggesting that the
compound did not strongly influence the nucleotide-induced
structural changes (Figure 3B). Additionally, it was reported that
when flavonoids bind near a tryptophan residue, they quench
its fluorescence (Conseil et al., 1998). Based on our NMR results,
myricetin appeared to interact near (10 A˚) Trp102; therefore, we
expected to see a fluorescence quench as myricetin bound to
DnaK. Indeed,myricetin quenched theTrp fluorescenceof nucle-
otide-free (Apo) DnaK (Figure 3C). Furthermore, when we added
saturating levels of ATP (2 mM), the apparent affinity (Kapp) of
myricetin decreased from 600 to 38 mM, suggesting that
myricetin had even better binding affinity when ATP was present
(Figure 3C). These results support a model in which myricetin
binds to a site on DnaK that is distinct from the ATP-binding
site and that ATP might even improve its affinity for DnaK.
The NMR chemical shift results were initially puzzling because
the distance between the responsive residues on the IB and IIB
subdomains in the available crystal structure (PDB code:
1DKG) (Harrison et al., 1997) seemed unlikely to be filled by
myricetin. However, the 1DKG crystal structure likely representsChemistry & Biology 18, 210an ‘‘open’’ form of DnaK’s NBD because it is a co-complex with
GrpE, and the IB and IIB subdomains have been proposed to be
closer to each other during the ATPase cycle (Bhattacharya et al.,
2009; Woo et al., 2009). To explore possible conformational
changes in DnaK and how they might impact myricetin binding,
we turned to computer simulations. First, a more dynamic struc-
ture of DnaK’s NBD was examined using unrestrained all-atom
Langevin Dynamics (LD) simulations. In these simulations the
presence of ATP or ADP/Pi significantly altered the conformation
of DnaK, bringing the IB and IIB subdomains into proximity.
Docking calculations based on those ‘‘closed’’ forms of DnaK
revealed that myricetin could occupy a position that satisfied
the observed NMR shifts (data not shown). Although it was satis-
fying that the observed contacts were consistent with the NMR
studies, the conformations were obtained without myricetin
present. Therefore, to determine a conformation for the system
that could incorporate any induced-fit phenomena, we next
conducted additional LDsimulations ofDnaK’sNBDwithmyrice-
tin, ADP, and Pi bound. The simulations started from the open
form, and the protein was allowed to collapse to a closed struc-
ture that best incorporated myricetin. These simulations also
supported the binding site between the IB and IIB subdomains
that was suggested by docking (Figure 3D). There was a wide
degree of sampling seen for myricetin, but the conformation
shown in the figure represents over half of the observed confor-
mations. Importantly, the observed bindingmodewas consistent
with the SAR. For example the critical 7-hydroxyl on ring A could
form hydrogen bonds to the b-phosphate of ADP and Lys55.
Furthermore, the three hydroxyls of the B ring formed hydrogen
bonds with the side-chain hydroxyl of Thr65 and the backbone
carbonyl oxygens of Pro62 and Ile88. Finally, the unsaturation
in ring C is most likely required for aligning ring B to form those
hydrogen bonds and van der Waals contacts with Pro90, and
a T-shaped aromatic stacking interaction with Phe67. Together,
these contacts appeared to assist the closing of the upper nucle-
otide-binding cleft, withmyricetin interactingwith both the IB and
IIB subdomains.
To test this model, we generated point mutants designed
to disrupt the interaction. Specifically, we targeted Lys55
and Asp233, which are proposed to make contacts with the
7-position hydroxyl on ring A and oxygens on ring C. In addition
we selected another residue far from the proposed myricetin-
binding site (Lys106) as a negative control (Figure 3E).
Substituting alanine in these locations generated the mutants
K55A, D233A, and K106A, which were well behaved by circular
dichroism (Chang et al., 2010). Using tryptophan fluorescence,
we then measured their apparent affinity for myricetin. Consis-
tent with the previous studies, the K55A and D233A mutants
bound myricetin only weakly (Kapp > 100 mM), whereas the
control mutant, K106A, was similar to the wild-type (Kapp 43 ±
5 mM and 55 ± 7 mM, respectively) (Figure 3E). These results
further supported the proposed flavonoid interaction site.
Thus far, these studies have focused on potential binding of
myricetin to DnaK. However, it also seemed possible that this
compound might directly interact with DnaJ, so we performed
isothermal calorimetry (ITC) studies to test this idea. Briefly, we
titrated myricetin into a solution of DnaJ (10 mM) and found
that it had no apparent affinity (Figure S3B). However, these titra-
tions were ‘‘noisy,’’ which precluded a definitive conclusion.–221, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 213
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Figure 3. Myricetin Binds to the IB and IIB Subdomains of DnaK NBD and Does Not Compete with ATP
(A) Mapping of the chemical shifts above 0.02 ppm (pink; Figure S3A) onto DnaK suggests that myricetin binds to the upper nucleotide cleft, between the IB and
IIB subdomains. (PDB: 1DKG). The approximate position of the nucleotide is shown for orientation, and the cartoon schematic is used to identify the subdomains.
(B) Saturating myricetin (100 mM) did not block tryptophan fluorescence (excitation 295 nm) in response to ATP. DnaK, 5 mM; ATP, 100 mM. Results are repre-
sentative of experiments performed in triplicate.
(C) ATP (2 mM) enhanced the apparent affinity of myricetin for DnaK, as measured by tryptophan fluorescence (Ex 295/Em. 342 nm). DnaK, 5 mM. Results are the
average of triplicates, and the error bars represent standard error of the mean. Error bars are often smaller than the symbols.
(D) A representative conformation of myricetin in DnaK, determined by LD simulations of the myricetin+ADP+Pi DnaK NBD (see the Experimental Procedures for
details). Contacts are in good agreement with observed NMR shifts and SAR data.
(E) Point mutations in K55A and D233A (highlighted in purple) significantly reduce binding of myricetin to DnaK, as measured by tryptophan fluorescence,
compared to wild-type and a control mutant (K106A). Results are the average of triplicate experiments, and the error bar represents the standard error of the
mean.
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Figure 4. Myricetin Specifically Blocked DnaJ Co-Chaperone Activities
(A) In ATPase assays, myricetin blocked DnaJ-mediated stimulation. In all the ATPase experiments, the results are the average of triplicates, and the error bars
represent standard error of the mean.
(B) Even at the highest concentrations, myricetin did not impact GrpE-mediated stimulation of ATP turnover.
(C) Similarly, myricetin was unable to block stimulation by a model substrate peptide. Additional tests of this idea can be found in Figure S4.
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J domain (residues 2–108), which is better behaved in ITC exper-
iments (unpublished data; Figure S3B). In these studies, myrice-
tin clearly failed to bind the J domain (Figure S3B). Although
these findings do not preclude weak binding of myricetin to
full-length DnaJ, they support a model in which themajor partner
for myricetin is DnaK.
Myricetin Specifically Blocks DnaJ’s Ability to Stimulate
ATP Turnover
To better understand the implications of these interactions, we
next measured whether myricetin could inhibit the ability of
DnaJ to stimulate DnaK’s ATPase activity. In the absence of
compound, DnaJ stimulated ATPase activity by approximately
4-fold, with a half-maximal value (KDnaJ) of 0.37 ± 0.03 mM (Fig-
ure 4A). Addition of myricetin at 200 mM completely suppressed
the stimulatory activity of DnaJ (Figure 4A), and even at 50 mM,
this compound dramatically weakened DnaJ’s activity (Fig-
ure 4A). Conversely, it had no effect on the intrinsic ATPase
activity of DnaK (Figure S4D), and it did not influence the stimu-
lation of DnaK by the other co-chaperone, GrpE (Figure 4B; Fig-
ure S4C). Finally, peptide substrates are known to stimulate ATP
turnover (Buchberger et al., 1994), so we tested whether myrice-
tin could block this activity. Using the high-affinity model
substrate, NRLLLTG, we found that myricetin had no effect on
peptide-mediated stimulation (Figure 4C; Figure S4B). Together,
these results strongly suggest that myricetin selectively blocks
the co-chaperone activity of DnaJ, without impacting the func-
tion of other DnaK partners.
As mentioned above, we found that myricetin did not bind to
the truncated J domain by ITC (Figure S3B). Therefore, weChemistry & Biology 18, 210wanted to specifically test whether this compound could block
J domain activity. Consistent with previous reports (Liberek
et al., 1991), we found that the J domain stimulates DnaK’s
ATP turnover (Figure S4A). Similar to what we observed with
full-length DnaJ, myricetin was able to block this stimulatory
activity (Figure S4A).
Because the binding sites for GrpE and myricetin are both
in the IB and IIB subdomains, we were interested in how this
co-chaperone might influence compound binding. We had
already found that myricetin did not suppress the stimulatory
activity of GrpE, but we were also interested in whether the co-
chaperone might impact myricetin-binding affinity. Toward that
question, we tested the activity of myricetin in the presence of
both DnaJ and GrpE. At saturating concentration of GrpE, we
found that the apparent affinity of myricetin was significantly
enhanced (Figure 5A). By altering the concentration of GrpE
and measuring the IC50 value of myricetin, we confirmed that
the co-chaperone potentiated the activity of the compound (Fig-
ure 5B). This result suggests that GrpE, by opening the nucleo-
tide-binding cleft of DnaK, may promote binding to myricetin,
thereby increasing its affinity during ATP cycling (Figure 5C).
Myricetin Reduces the Ability of DnaJ to Stimulate
the Substrate-Binding Activity of DnaK
Because myricetin appeared to block the ability of DnaJ to
accelerate ATP turnover in DnaK, we hypothesized that it might
also interrupt substrate binding by reducing conversion to the
high-affinity, ADP-bound state. To test this hypothesis we
measured DnaK’s binding to amodel substrate, luciferase, using
an ELISA-based approach. Briefly, we partially digested lucif-
erase to increase the exposed hydrophobic regions and then–221, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 215
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Figure 5. GrpE Enhanced Myricetin Activity
on DnaK-DnaJ
(A) GrpE (2 mM) decreased the IC50 of myricetin for
the DnaK-DnaJ complex.
(B) Dose dependence of GrpE action on the IC50
value of myricetin. DnaK, 0.6 mM; DnaJ, 1 mM.
Results are the average of triplicates, and the error
bars represent standard error of the mean.
(C) Model for how GrpE might impact myricetin
binding. Only the NBD is shown for clarity. Myrice-
tin does not blockGrpE-mediated stimulation, so it
either dissociates prior to the next cycle or other-
wise does not interfere with GrpE function.
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anti-DnaK antibody to measure bound chaperone, we first
confirmed that DnaJ is able to stimulate DnaK’s binding to immo-
bilized luciferase (Figure 6A) (Laufen et al., 1999). Maximal
stimulation was observed at 60 nM of DnaJ, and at higher levels,
DnaK’s binding gradually diminished, likely because of
competition between DnaJ and DnaK for shared sites on lucif-
erase. We found that 20 mM myricetin inhibited DnaJ-mediated
stimulation of binding, with the amount of DnaJ required to
promote binding increased from 62 nM to 1 mM, and themaximal
amount of bound DnaK also decreased by approximately 40%
(Figure 6A).
Myricetin Inhibits Binding of DnaJ to DnaK
Binding of myricetin to DnaK might block the ability of DnaJ to
act on DnaK through at least two different mechanisms. In
theory, myricetin might either (a) inhibit the physical interactions
between DnaJ and DnaK, or (b) block the allosteric activity of
DnaJ on DnaK without directly impacting the strength of the
protein-protein interaction. To begin to differentiate between
these models, we directly measured the binding of DnaJ to
DnaK by Fo¨rster resonance energy transfer (FRET) (Ruan et al.,
2009). Briefly, DnaK was labeled with the fluorescent donor
Alexa 488 (Em. 525 nm) and DnaJ with Black Hole Quencher-
10 (BHQ-10), a FRET acceptor that absorbs strongly around
507 nm. In the absence of myricetin, the apparent affinity
(Kapp) between DnaJ and DnaK was estimated to be approxi-
mately 560 nM, consistent with previous studies (Suh et al.,
1998). Addition of myricetin significantly reduced binding of
DnaJ to DnaK (Figure 6B), with the Kapp weakened by 5.3-fold
(at 25 mM myricetin). A control flavonoid, (±)-catechin, did not
inhibit this interaction (Figure 6B) Together, these results suggest216 Chemistry & Biology 18, 210–221, February 25, 2011 ª2011 Elsevier Ltd All rights reservthat myricetin inhibits DnaJ by preventing
contacts between the chaperone and co-
chaperone (Figure 6C).
DISCUSSION
Design of High-Throughput
Screens for the DnaK-DnaJ
Combination: Methods for
Targeting Multi-Protein Complexes
A key effort in chemical biology is to
identify inhibitors of protein-protein inter-actions (Grant, 2009; May et al., 2007; Zhang et al., 2009).
Furthermore, allosteric modulators of these interactions are
becoming an increasingly important goal in screening
campaigns. With these concepts in mind, we targeted the
DnaK-DnaJ combination. The key design criteria were (a) screen
in the presence of high ATP concentrations (> > Km), and (b)
screen against the reconstituted combination of DnaK and
DnaJ. The first design aspect (i.e., high ATP) was chosen to favor
identification of allosteric, rather than competitive, modulators.
For the DnaK system this criterion is important because of the
high cellular levels of ATP and its unusually tight binding to nucle-
otide (mid-nanomolar) (Massey, 2010). The second design
aspect (i.e., inclusion of DnaJ) was selected because a majority
of the measurable signal would be expected to emerge from
stimulatory activities of the co-chaperone. Thus, compounds
appearing as ‘‘actives’’ in the screen might be expected to
preferentially influence the co-chaperone-dependent activity
(e.g., following the axiom, ‘‘you get what you screen for’’).
Together, we term this approach ‘‘gray box’’ screening because
its goals are distinct from experiments that target purified
proteins. Rather, it has more in common with ‘‘black box,’’
cell-based screens but with fewer possible options for target
deconvolution.
‘‘Gray box’’ screens might be particularly appropriate for
systems, such as Hsp70s, that are regulated by multiple stimu-
latory and inhibitory protein partners. Hsp70, being the hub of
many cellular activities (Daugaard et al., 2007), is regulated by
many co-chaperones, including J domain-containing proteins,
nucleotide exchange factors (e.g., GrpE, BAGs, Hsp110, and
HspBP1), and tetratricopeptide repeat (TPR) motif-containing
proteins (e.g., CHIP and HOP) (Bukau et al., 2006; Daugaard
et al., 2007; Meimaridou et al., 2009). Interestingly, many ofed
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Figure 6. Myricetin Blocked DnaJ-Mediated
Enhancement of DnaK’s Binding to
Substrate and Interfered with the DnaK-
DnaJ Interaction
(A) Myricetin inhibited the DnaJ-mediated stimula-
tion of DnaK binding to partially digested firefly
luciferase. Each data point is the average of tripli-
cates, and the error bars represent the standard
error of the mean.
(B) Labeled DnaJ was titrated into fluorescent
DnaK and the apparent binding affinity (Kapp)
measured by FRET. Myricetin, but not the control
compound (catechin), partially blocked binding.
The results are the average of triplicates, and the
error bars represent standard error of the mean.
Further results are shown in Figure S5.
(C) Model for the allosteric mechanism of myrice-
tin. By impacting the clam-like motions of the sub-
domains, myricetin might impact DnaJ binding at
a distal site. The hydrophobic cleft between sub-
domains IA and IIA is shown in green.
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rate, and it might be a particularly attractive surrogate for
emergent chaperone functions. In fact we have used thismethod
to identify chemical probes against the mammalian Hsp70
system that have revealed critical roles for ATP turnover
in models of protein misfolding disease (Jinwal et al., 2009;
Wisen et al., 2010). We anticipate that a variety of other, impor-
tant multi-protein systems, such as chromatin-remodeling
complexes, the mTor complex, or the exocyst, might be simi-
larly targeted. Finally, it is also worth strongly emphasizing
that the phenotypic complexity of other systems or technical
issues may make a ‘‘gray box’’ approach cumbersome or
undesirable.
Identification of an Unanticipated Allosteric
Site on DnaK-DnaJ
In our natural product screens, we identified flavonoids as
inhibitors of the DnaK-DnaJ complex. There are >9000 natu-
rally occurring flavonoids (Martens and Mithofer, 2005), and
these compounds have been reported to have antioxidant,
antitumor, antiviral, antifungal, and antibacterial activities
(Friedman, 2007; Khan and Mukhtar, 2008; Yang et al., 2009).
These compounds carry out their diverse biological activities
by targeting various enzymes, including receptor tyrosine
kinases, cyclin-dependent kinases, and P-glycoprotein (Conseil
et al., 1998; Friedman, 2007; Gamet-Payrastre et al., 1999;
Teillet et al., 2008). The diversity of these targets suggests
that flavonoids have relatively promiscuous binding profiles.
Yet, plant-derived flavonoids have been productive and inter-
esting starting points for drug discovery (Cuccioloni et al.,
2009; Shapiro, 2004; Wiseman et al., 2010). Interestingly, one
common feature of flavonoid targets is that they often bind
ATP (Gamet-Payrastre et al., 1999; Teillet et al., 2008);Chemistry & Biology 18, 210–221, February 25, 2011however, NMR, fluorescence, and
modeling studies suggested that the
binding site of myricetin on DnaK is
distinct from the ATP-binding pocket(Figure 3). This finding is consistent with recent studies on
other flavonoids (Wiseman et al., 2010). Despite this interesting
mechanism, we found that the SAR for inhibition of DnaK-DnaJ
is similar to that reported for flavonoids against other enzymes,
such as receptor tyrosine kinase or protein kinase C (Gamet-
Payrastre et al., 1999; Teillet et al., 2008). Thus, it is highly
unlikely that myricetin or its close derivatives will bind selec-
tively to DnaK-DnaJ in vivo. Rather, they might have been
selected through evolution for their broad spectrum of targets
(Khan and Mukhtar, 2008), an interesting alternative to the
single-target, drug discovery model.
Although myricetin is not a selective or particularly potent
inhibitor of DnaK-DnaJ, these results suggest a new ‘‘druggable’’
site on the chaperone, and they reveal a previously unanticipated
allosteric network in DnaK. We found that myricetin, by binding
to the upper nucleotide-binding cleft between the IB and IIB
subdomains, specifically interfered with binding to DnaJ, and
subsequently, it interrupted co-chaperone stimulated activities.
How can myricetin binding in the IB and IIB subdomain affect
a remote site between the IA and IIA subdomains, where DnaJ
binds to DnaK? Both NMR and modeling studies suggest that
the IB and IIB subdomains move closer to each other in the
‘‘closed,’’ ATP-bound conformation (Bhattacharya et al., 2009;
Woo et al., 2009). Simultaneously, the hydrophobic surface
between the IA and IIA subdomains is expected to be more
accessible in the ATP-bound form (Bhattacharya et al., 2009;
Woo et al., 2009). Thus, it seems plausible that domains I and
II undergo a clam-like movement during ATP hydrolysis, linking
closure of the IB and IIB subdomains to the opening of IA and
IIA. For that reason, if myricetin inserts between the IB and IIB
subdomains, it might disrupt the DnaJ docking site at the distal
IA and IIA region (Figure 6C). This model clearly requires
additional structural evaluation.ª2011 Elsevier Ltd All rights reserved 217
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Hsp70s are highly conserved molecular chaperones that
play crucial roles in maintaining cellular proteostasis. They
are also emerging drug targets for a range of diseases,
including cancer, microbial infection, and neurodegenera-
tion. In this study we identified myricetin as an inhibitor of
the E. coli Hsp70, DnaK. NMR and modeling studies sug-
gested that this compound binds to a flexible site between
the IB and IIB subdomains of DnaK and that it specifically
blocks the activities of the co-chaperone DnaJ. This mecha-
nism is unexpected because myricetin’s binding site is at
least 20 A˚ from where DnaJ interacts with DnaK, in a region
not previously implicated in DnaJ-mediated allostery. Thus,
although myricetin, because of its poor selectivity and
stability, is unlikely to be a suitable scaffold for drug
development per se, this work identified an unanticipated
allosteric site that might be suitable for targeting. Finally,
this study provides a ‘‘gray box’’ strategy for identifying
modulators of protein-protein interactions in reconstituted
multi-protein complexes in vitro.
EXPERIMENTAL PROCEDURES
Materials and General Protocols
Apigenin, baicalein, catechin, EGCG, epigallocatechin, luteolin, morin, myrice-
tin, quercetin, and rhamnetin were purchased from Sigma (St. Louis, MO,
USA). Taxifolin and kaempferol were bought from Fluka (Switzerland). Hieracin
and epicatechin gallate were acquired from MicroSource (Gaylordsville, CT,
USA). The ATPase assays were performed using a previously established
protocol (Chang et al., 2008a).
Plasmid Construction and Protein Purification
DnaK, GrpE, and DnaJ were purified, and the His-tags were cleaved as previ-
ously indicated (Chang et al., 2010). Nucleotide-free (apo) DnaK was purified
by a slight modification of the previous protocol. Briefly, after the first low-salt
washing step of the ATP column, apo-DnaK was eluted using 50 mM Tris
buffer (pH 7.5) containing 1 M NaCl. His-tagged J domain (residues 2–108)
was first purified as previously mentioned (Chang et al., 2010), but an addi-
tional purification step using a Superdex 200 gel filtration column (GE Health-
care) was included. Purified DnaJ, J domain, GrpE, and DnaK were dialyzed
into 25 mM Tris buffer (pH 7.5) containing 10 mM KCl (for DnaJ and J domain,
150 mM KCl) and 5 mM MgCl2, and stored at 80C.
Construction of Natural Extract Library and Screening
against DnaK/DnaJ Complex
Approximately 300 mg of powdered natural product was extracted with
500 ml of methanol. After vortexing and 15 min of sonication, the samples
were centrifuged at 10,000 rpm for 5 min, and the supernatant was collected.
After removing the organic solvent, the dried material was suspended in
DMSO at 1 mg/ml. The resulting extract library was screened in the ATPase
assay at 40 mg/ml final concentration, using a previously described protocol
(Chang et al., 2008a). The concentrations of DnaJ and DnaK were 1.0 and
0.6 mM, respectively.
Identification of the Active Component from Tea
White tea leaves were extracted with EtOAc, MeOH, and acetone. The
combined extracts were then concentrated in vacuo, and the residue was
partitioned between H2O and CH2Cl2. The organic phase was partitioned
between 90% MeOH and n-hexanes, and the aqueous MeOH fraction was
further partitioned between 60% MeOH and CH2Cl2. Using ATPase assays
for bioactivity-guided fractionation, we identified the 60% MeOH fraction as
the sample with inhibitory activity against E. coli DnaK. This sample was
then subjected to ODS flash chromatography (Supelco, Bellefonte, PA, USA)218 Chemistry & Biology 18, 210–221, February 25, 2011 ª2011 Elsewith aqueous MeOH, yielding six fractions. The most active fraction was
purified by reversed-phase HPLC (Beckman-Coulter, Brea, CA, USA) on
Waters Spherisorb ODS-2 using a linear gradient elution of an aqueous
MeOH system, followed by reversed-phase HPLC with 20% aqueous
MeOH. This procedure yielded ECG as the major active component. The
identification of this compound was confirmed by comparison of the 1H
NMR spectrum and ESI-MS spectrum with those of an authentic sample
purchased from MicroSource (Figure S1).
SAR Studies
To identify available molecules structurally similar to ECG, we performed simi-
larity searches for the core 2-phenyl benzopyran in the >100,000 compounds
of theM-screen database (University ofMichigan). From this analysis, 80 flavo-
noids were selected. Within the collection, 59 compounds were selected from
the MS2000 library (MicroSource), ten from the Maybridge HitFinder library
(Maybridge), four from the NIH Clinical Collection (BioFocus), four from the
ChemDiv library, one from the Chembridge library, and one from the National
Cancer Institute Collection. The compounds were ‘‘cherry-picked’’ and serially
diluted (1:2) in ddH2O from 125 to 0.9 mM into white, 384-well low-volume
plates (4 ml/well). Compounds were tested in duplicate, using a previously
described protocol (Miyata et al., 2010). Flavonoids that showed inhibition or
had structure similar to active compounds were purchased and retested in
96-well malachite green-based ATPase assay against DnaK/J complex (at
0.6 and 1 mM) as described (Chang et al., 2008a).
NMR Spectroscopy
The NMR experiments were carried out as previously described (Wisen et al.,
2010). Briefly, 15N-labeled DnaK2-388 was purified and concentrated to
approximately 0.5 mM, exchanged into NMR buffer (25 mM Tris, 10 mM
MgCl2, 5 mM KCl, 10%
2H2O, 0.01% sodium azide [pH 7.1]), and stored
at80C. Prior to NMR analysis, DnaK2-388 samples were thawed and supple-
mented with 5 mM ADP. After collecting reference spectra, myricetin was
titrated to a final concentration of 1mM from a 100mMstock in DMSO.Control
experiments showed that DMSO alone had had no detectable effects on
the spectrum of DnaK2-388 at concentrations up to 1% and that it had minimal
effects on the spectra of DnaK2-605 at the same concentration. Two-
dimensional HSQC-TROSY NMR spectra were collected at 30C on a cryo-
probe-equipped Varian Inova 800 MHz spectrometer, with data collection
times of approximately 2 hr per spectrum. NMR data were processed using
NMRPipe and analyzed with Sparky. Combined 1H and 15N chemical shift
changes were measured using a weighted function and the assignments
generated previously. Residues were selected as significant if the chemical
shift was greater than 0.02 ppm (Figure S3A).
Protein Dynamic Simulations
Coordinates of E. coli DnaK NBD were obtained from the PDB (PDB: 1DKG)
(Harrison et al., 1997), and the co-crystallized nucleotide-exchange factor
GrpE was discarded. The missing side chains and short loops (%5 amino
acids) of NBD were introduced using Molecular Operating Environment
(v2005.06) (Chemical Computing Group, Inc., Quebec, Canada) and PyMOL
(DeLano Scientific, Palo Alto, CA, USA). AMBER 10 (Case et al., 2008) package
was used to perform unrestrained all-atom LD simulations. The protein
was modeled using the FF99SB force field (Hornak et al., 2006). Model II of
a modified Generalized Born approach (Onufriev et al., 2004) was used to
implicitly model aqueous solvation. Collision frequency of 1 ps1 was used.
Three states of DnaK were simulated using LD: apo-NDB, ATP-bound NDB,
and ADP+Pi-bound NDB. Because 1DKG was crystallized without bound
cofactors, positions for these cofactors were obtained by superimposing
the crystal structures of the closely related homolog bovine Hsc70. ATP,
Mg2+, and K+ ions were obtained from PDB: 1KAZ (O’Brien et al., 1996), and
ADP, PO4
3, Mg2+, and K+ ions were obtained from PDB: 1BUP (Sousa and
McKay, 1998).
Parameters for Pi and Mg
2+ were generated using the ANTECHAMBER
module of AMBER, and AM1-BCC charges (Jakalian et al., 2002) were applied.
Nucleotide parameters developed by Meagher et al. (2003) were used for ATP
and ADP. The SHAKE algorithm (Ryckaert et al., 1977) was used to restrain
hydrogen atoms. Hydrogen atoms were first minimized, followed by residue
side chains, and finally an all-atom minimization. Five independent LDvier Ltd All rights reserved
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different random-number seeds. The nonbonded interactions’ cutoff was set
to 999 A˚. Default dielectric values were used: interior = 1 and exterior =
78.5. Heating and restrained equilibrations were followed. The system was
heated gradually from 100 to 300 K during the first two equilibrations, and
the temperature remained at 300 K for the remaining equilibrations and
production phase. Restraints were placed on all heavy atoms and gradually
relaxed over the first four equilibrations using force constants from 2.0 to
0.1 kcal/mol 3 A˚2. Restraints were maintained on backbone atoms in the fifth
equilibration using a force constant of 0.1 kcal/mol 3 A˚2. All restraints were
removed in the sixth equilibration. The first three equilibrations were performed
for 20 ps each, followed by 50 ps for the fourth and fifth equilibrations. The
sixth, unrestrained equilibration was run for 740 ps, and the production phase
was run for 5 ns. A time step of 1 fs was used, and snapshots were collected
every 1 ps.
For the simulations of myricetin bound to DnaK, myricetin was docked into
the initial NBD+ADP+Pi structure using AutoDock 4.01 (Morris et al., 2009).
This was the same structure built from the crystal structures and used to
initiate the LD simulations. A grid box of (90, 100, 94) points and 0.375 A˚
spacing was centered at the interface between IB/IIB subdomains and over
the residues with myricetin-induced NMR chemical shifts. The docking calcu-
lation involved a Lamarckian genetic algorithm (Morris et al., 1998); an initial
population size of 200 and a maximum of 75 million energy evaluations were
applied. The lowest-energy pose of myricetin, which was consistent with the
NMR chemical shifts, was added to the NBD. GAFF (Wang et al., 2004) with
AM1-BCC charges was used to parameterize myricetin in ANTECHAMBER.
Five independent LD simulations of the myricetin+ADP+Pi+NBD system
were generated using protocol described above.
Tryptophan Fluorescence
The tryptophan fluorescence experiments were carried out as previously
reported with slight modification (Theyssen et al., 1996). To study whether
myricetin blocked ATP binding, 6 mM apo-DnaK was incubated with 125 mM
myricetin with total volume of 40 ml in a 96-well black plate (Corning) for 1 hr
at 37C. Next, 10 ml of 500 mM ATP or buffer (200 mM Tris, 40 mM KCl,
12 mM MgCl2 [pH 7.4]) was added to each well, and then the emission spec-
trum between 300 and 400 nm was recorded (excitation at 295 nm) using
a SpectraMax M5 (Molecular Devices). Alternatively, the tryptophan fluores-
cence quench caused by myricetin was measured as follows. Myricetin, at
concentration indicated in the figure, was added to 5 mM of DnaK in the pres-
ence or absence of 2 mM ATP with a total volume of 30 ml in a black 96-well
plate, and the fluorescence at 342 nm (excitation at 295 nm) was measured
by SpectraMax M5, and the controls with every component except DnaK
was subtracted from the final values. Experiments described in Figure 3E
were carried out as above but with slightly different DnaK and ATP concentra-
tions (3 mM and 1 mM, respectively) in lower total volume (20 ml), and the read-
ings were performed in black, 384-well round-bottom plates (Corning).
ELISA
Binding of DnaK to denatured luciferase was measured as previously
described (Miyata et al., 2010).
DnaK-DnaJ Interaction by FRET
The assays were carried out as recently reported with slight modifications
(Ruan et al., 2009). DnaK (10 mg/ml; 200 ml) was labeled with Alexa Fluor
488 5-TFP (Invitrogen, Carlsbad, CA, USA), and DnaJ (10 mg/ml; 300 ml)
was labeled using the N-hydroxysuccinimide ester of BHQ-10 Carboxylic
Acid (Biosearch Technologies, Novato, CA, USA). Both reactions were carried
out at a 10:1 molar ratio of dye:protein in bicarbonate buffer (100mMNaHCO3,
5mMMgCl2, 10mMKCl [pH 9.5]). DnaKwas labeled for 1.5 hr at room temper-
ature, whereas DnaJ was labeled for 1 hr at 30C. After the incubation, the
unreacted dye was removed, and the buffer was exchanged to 25 mMHEPES
buffer (pH 7.4) using Zeba Desalt Spin Columns (2 ml, MWCO = 7000 Da)
(Thermo Scientific, Rockford, IL, USA). The average extent of labeling for
DnaK and DnaJ was then determined to be approximately 2.5 and 0.5 fluoro-
phore/dye per protein, respectively, using the 3495 = 71,000 M
1cm1 (Alexa
Fluor 488) and 3507 = 30,000 M
1 cm1 (BHQ-10). Labeled DnaK was diluted
to 100 nM using 100 mM Tris-HCl buffer (20 mM KCl, 6 mM MgCl2, 0.01%Chemistry & Biology 18, 210Triton X-100 [pH 7.45]) containing compound (or solvent control) and 2 mM
ATP. After preincubation at room temperature for 30 min, 10 ml of this diluted
sample was added to 384-well, black round-bottom plates (Corning). Next,
10 ml of a BHQ-10-labeled DnaJ solution was added to each well, and the
samples were incubated at 37C for 30 min. After the incubation, the fluores-
cence at 525 nm (Ex. 480, cutoff 515 nm) was measured using a SpectraMax
M5microplate reader. The results were analyzed by GraphPad Prism 4.0 using
a hyperbolic fit with a nonzero intercept:DF =DFmax3 [J]/(Kapp+ [J]) + b, where
DF is fluorescence change, DFmax is maximum fluorescence change, Kapp is
apparent Kd, and [J] is DnaJ concentration.
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